Skip to content

Search across repositories

Find data for your analysis

602 datasets from 5 repositories. Filter by the analysis you need to run, not by what a repository says a dataset contains. How capability is measured.

206 of 602 datasets

  • MSK MetTropism (MSK, Cell 2021)
    OpenMachine-extracted
    msk_met_2021cBioPortal25,775 casesMixed Cancer Types

    Why it fits: survival endpoints, median follow-up 17.4 months; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • MSK-CHORD (MSK, Nature 2024)
    OpenMachine-extracted
    msk_chord_2024cBioPortal24,950 casesMixed Cancer Types

    Why it fits: survival endpoints, median follow-up 2.1 years; 4 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panelTreatment records

    No citable accession, so reuse cannot be traced

  • MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017)
    OpenMachine-extracted
    msk_impact_2017cBioPortal10,336 casesMixed Cancer Types

    Why it fits: survival endpoints, median follow-up 11.0 months; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Breast Cancer (MSK, Nat Genet 2025)
    OpenMachine-extracted
    breast_msk_2025cBioPortal3,116 casesInvasive Breast Carcinoma

    Why it fits: survival endpoints, median follow-up 3.3 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Acute Myeloid Leukemia
    MixedProject-curated
    TARGET-AMLGDC2,492 casesMyeloid Leukemias, Not Applicable

    Why it fits: treatment response recorded; survival endpoints, median follow-up 3.5 years; 9 measurement types on the same cohort

    2,492 children and young adults with acute myeloid leukaemia - the largest paediatric cancer genomics cohort in this corpus, with 3.5 years of median follow-up and therapeutic agents recorded for 35% of cases.

    Clinical dataCopy numberDNA methylationmicroRNABulk RNA sequencingStructural variants+3 more

    137 articles analyzed these data - 695 cite the paper

  • Pancreatic Adenocarcinoma (MSK, Nat Med 2024)
    OpenMachine-extracted
    pdac_msk_2024cBioPortal2,336 casesPancreas

    Why it fits: survival endpoints, median follow-up 13.5 months; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)
    OpenMachine-extracted
    luad_mskcc_2023_met_organotropismcBioPortal2,298 casesLung Adenocarcinoma

    Why it fits: survival endpoints, median follow-up 3.1 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Prostate Cancer (MSK, Clin Cancer Res 2024)
    OpenMachine-extracted
    prostate_msk_2024cBioPortal2,257 casesProstate

    Why it fits: survival endpoints, median follow-up 3.5 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Sarcoma (MSK, Nat Commun. 2022)
    OpenMachine-extracted
    sarcoma_mskcc_2022cBioPortal2,138 casesSoft Tissue

    Why it fits: survival endpoints, median follow-up 22.5 months; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • CPTAC-Brain, Head and Neck, Kidney, Lung, Pancreas, Uterus
    Underused opportunityMixedProject-curated
    CPTAC-3GDC1,866 casesNot Applicable, Transitional Cell Papillomas and Carcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 22.9 months; 9 measurement types on the same cohort

    1,866 tumors across six cancer types with genomics in the GDC and proteomics in the PDC - the largest prospectively collected proteogenomic cohort, with recurrence recorded for 78% of cases.

    Copy numberDNA methylationmicroRNABulk RNA sequencingSingle-cell RNA sequencingStructural variants+3 more

    25 articles analyzed these data - 688 cite the paper

  • Breast Cancer (MSK, Cancer Cell 2018)
    OpenMachine-extracted
    breast_msk_2018cBioPortal1,756 casesBreast

    Why it fits: survival endpoints, median follow-up 3.4 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • TMB and Immunotherapy (MSK, Nat Genet 2019)
    OpenMachine-extracted
    tmb_mskcc_2018cBioPortal1,661 casesMixed Cancer Types

    Why it fits: survival endpoints, median follow-up 11.0 months; no access request needed

    Structural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Acute Lymphoblastic Leukemia - Phase II
    MixedMachine-extracted
    TARGET-ALL-P2GDC1,587 casesLymphoid Leukemias

    Why it fits: survival endpoints, median follow-up 7.7 years; 7 measurement types on the same cohort

    Clinical dataCopy numbermicroRNABulk RNA sequencingStructural variantsWhole genome sequencing+1 more

    42 articles analyzed these data

  • Molecular Profiling to Predict Response to Treatment for Acute Lymphoblastic Leukemia
    Underused opportunityMixedProject-curated
    MP2PRT-ALLGDC1,510 casesAcute Lymphoblastic Leukemia, Lymphoid Leukemias

    Why it fits: treatment response recorded; survival endpoints, median follow-up 8.3 years; 6 measurement types on the same cohort

    1,510 children with acute lymphoblastic leukaemia from Children's Oncology Group trials, with whole genome sequencing, 8.4 years of median follow-up, and a named treatment regimen and response recorded for every single case.

    Clinical dataCopy numberBulk RNA sequencingStructural variantsWhole genome sequencingWhole exome sequencing

    0 articles analyzed these data

  • Prostate Adenocarcinoma (MSK, Clin Cancer Res. 2022)
    OpenMachine-extracted
    prad_pik3r1_msk_2021cBioPortal1,417 casesProstate Adenocarcinoma

    Why it fits: survival endpoints, median follow-up 2.2 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Hepatocellular Carcinoma (MSK, Clin Cancer Res 2024)
    OpenMachine-extracted
    hcc_msk_2024cBioPortal1,370 casesHepatocellular Carcinoma

    Why it fits: survival endpoints, median follow-up 18.4 months; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Hepatobiliary Cancer (MSK, 2026)
    OpenMachine-extracted
    biliary_tract_msk_2026cBioPortal1,254 casesBiliary Tract

    Why it fits: survival endpoints, median follow-up 10.6 months; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Bladder Cancer (MSK, Cell Reports 2022)
    OpenMachine-extracted
    paired_bladder_2022cBioPortal1,244 casesBladder/Urinary Tract

    Why it fits: survival endpoints, median follow-up 2.6 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)
    OpenMachine-extracted
    cll_broad_2022cBioPortal1,149 casesChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Why it fits: survival endpoints, median follow-up 6.6 years; 4 measurement types on the same cohort; no access request needed

    Bulk RNA sequencingStructural variantsTargeted DNA panelTreatment records

    No citable accession, so reuse cannot be traced

  • Neuroblastoma
    MixedMachine-extracted
    TARGET-NBLGDC1,132 casesNot Applicable, Neuroepitheliomatous Neoplasms

    Why it fits: survival endpoints, median follow-up 6.2 years; 7 measurement types on the same cohort

    Clinical dataDNA methylationBulk RNA sequencingStructural variantsTargeted DNA panelWhole genome sequencing+1 more

    49 articles analyzed these data - 989 cite the paper

  • Metastatic Non-Small Cell Lung Cancer (MSK, Nature Medicine 2022)
    OpenMachine-extracted
    nsclc_ctdx_msk_2022cBioPortal1,127 casesNon-Small Cell Lung Cancer

    Why it fits: survival endpoints, median follow-up 16.6 months; 4 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panelTreatment records

    No citable accession, so reuse cannot be traced

  • Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)
    OpenMachine-extracted
    crc_msk_2017cBioPortal1,099 casesColorectal Adenocarcinoma

    Why it fits: survival endpoints, median follow-up 2.4 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Breast Invasive Carcinoma
    MixedProject-curated
    TCGA-BRCAGDC + IDC1,098 casesCystic, Mucinous and Serous Neoplasms, Adenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.3 years; 12 measurement types on the same cohort

    1,098 breast tumors measured twelve ways across GDC and IDC, with treatment outcome on 64% of cases - the most reused dataset in this corpus and still the reference cohort for method development.

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    2,373 articles analyzed these data - 9,914 cite the paper

  • Adenoid Cystic Carcinoma Project (J Clin Invest 2019)
    OpenMachine-extracted
    acc_2019cBioPortal1,045 casesAdenoid Cystic Carcinoma

    Why it fits: survival endpoints, median follow-up 4.1 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Multiple Myeloma CoMMpass Study
    MixedMachine-extracted
    MMRF-COMMPASSGDC995 casesPlasma Cell Tumors

    Why it fits: survival endpoints, median follow-up 2.1 years; 5 measurement types on the same cohort

    Copy numberBulk RNA sequencingStructural variantsWhole genome sequencingWhole exome sequencing

    125 articles analyzed these data

  • Glioma (MSK, Clin Cancer Res 2019)
    OpenMachine-extracted
    glioma_mskcc_2019cBioPortal924 casesDiffuse Glioma

    Why it fits: survival endpoints, median follow-up 20.3 months; 4 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panelTreatment records

    No citable accession, so reuse cannot be traced

  • Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)
    OpenMachine-extracted
    egc_msk_2023cBioPortal902 casesEsophagus/Stomach

    Why it fits: survival endpoints, median follow-up 21.1 months; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)
    OpenMachine-extracted
    aml_ohsu_2022cBioPortal805 casesAcute Myeloid Leukemia

    Why it fits: survival endpoints, median follow-up 11.0 months; 3 measurement types on the same cohort; no access request needed

    Bulk RNA sequencingStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • NCI Cancer Model Development for the Human Cancer Model Initiative
    Underused opportunityMixedProject-curated
    HCMI-CMDCGDC + IDC805 casesDuctal and Lobular Neoplasms, Complex Mixed and Stromal Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 15.8 months; 10 measurement types on the same cohort

    805 next-generation cancer models - organoids and other patient-derived systems - with whole genome sequencing on 804 and the matched patient tumor, spanning many rare cancers.

    Clinical dataCopy numberHistopathology slidesDNA methylationmicroRNARadiology imaging+4 more

    6 articles analyzed these data

  • Cerebrospinal Fluid Circulating Tumor DNA (MSK, Acta Neuropathol Commun 2024)
    OpenMachine-extracted
    csf_msk_2024cBioPortal711 casesMixed Cancer Types

    Why it fits: survival endpoints, median follow-up 2.3 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Melanoma (MSK, Clin Cancer Res 2021)
    OpenMachine-extracted
    mel_mskimpact_2020cBioPortal696 casesCutaneous Melanoma

    Why it fits: survival endpoints, median follow-up 3.8 years; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • High-Risk Wilms Tumor
    MixedMachine-extracted
    TARGET-WTGDC652 casesComplex Mixed and Stromal Neoplasms

    Why it fits: survival endpoints, median follow-up 5.9 years; 8 measurement types on the same cohort

    Clinical dataDNA methylationmicroRNABulk RNA sequencingStructural variantsTargeted DNA panel+2 more

    72 articles analyzed these data - 296 cite the paper

  • MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)
    OpenMachine-extracted
    msk_access_2021cBioPortal617 casesMixed Cancer Types

    Why it fits: survival endpoints, median follow-up 14.9 months; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Glioblastoma Multiforme
    MixedProject-curated
    TCGA-GBMGDC + IDC617 casesGliomas, Not Reported

    Why it fits: treatment response recorded; survival endpoints, median follow-up 12.0 months; 12 measurement types on the same cohort

    617 glioblastomas with twelve measurement types including radiology on 607 and pathology slides on 389 - the reference glioma cohort, with a median follow-up of 12.0 months.

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    1,399 articles analyzed these data - 6,091 cite the paper

  • Ovarian Serous Cystadenocarcinoma
    MixedMachine-extracted
    TCGA-OVGDC + IDC608 casesNot Reported, Cystic, Mucinous and Serous Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.7 years; 11 measurement types on the same cohort

    Clinical dataCopy numberHistopathology slidesDNA methylationmicroRNAReverse phase protein array+5 more

    641 articles analyzed these data - 6,322 cite the paper

  • Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)
    OpenMachine-extracted
    luad_mskcc_2020cBioPortal604 casesLung Adenocarcinoma

    Why it fits: survival endpoints, median follow-up 23.4 months; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Lung Adenocarcinoma
    MixedMachine-extracted
    TCGA-LUADGDC + IDC585 casesCystic, Mucinous and Serous Neoplasms, Ductal and Lobular Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 21.6 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    2,831 articles analyzed these data - 4,700 cite the paper

  • Acute Myeloid Leukemia (OHSU, Nature 2018)
    OpenMachine-extracted
    aml_ohsu_2018cBioPortal562 casesAcute Myeloid Leukemia

    Why it fits: survival endpoints, median follow-up 10.2 months; 3 measurement types on the same cohort; no access request needed

    Bulk RNA sequencingStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Uterine Corpus Endometrial Carcinoma
    MixedMachine-extracted
    TCGA-UCECGDC + IDC560 casesNot Reported, Epithelial Neoplasms, NOS

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.5 years; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    387 articles analyzed these data - 4,497 cite the paper

  • Kidney Renal Clear Cell Carcinoma
    MixedMachine-extracted
    TCGA-KIRCGDC + IDC537 casesAdenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 3.2 years; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    1,245 articles analyzed these data - 2,845 cite the paper